Blepharitis

Latest News

Image Credit: © ohishift - stock.adobe.com
Safety, efficacy of lotilaner ophthalmic solution for Demodex blepharitis treatment

March 31st 2023

Though there is no current FDA-approved treatment, lotilaner ophthalmic solution, 0.25%, is the first drug designed to treat and target the underlying cause of Demodex blepharitis.

SECO 2023: Drugs of the future
SECO 2023: Drugs of the future

March 2nd 2023

Eye care therapies on the move: What’s in the pipeline
Eye care therapies on the move: What’s in the pipeline

September 16th 2022

Effective treatments for presbyopia, myopia, demodex
Effective treatments for presbyopia, myopia, demodex

March 12th 2022

Protect patients’ eyes by encouraging a three-step ocular wellness regimen
Protect patients’ eyes by encouraging a three-step ocular wellness regimen

October 9th 2020

Latest CME Events & Activities

(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action

View More

Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)

View More

Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)

View More

(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action

View More

(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon

View More

(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon

View More

(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium

View More

(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment

View More

(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment

View More

(CME) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types

View More

(COPE) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types

View More

(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape

View More

(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape

View More

Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (CME Credit)

View More

Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (COPE Credit)

View More

Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)

View More

Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)

View More

SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management

View More

EnVision Summit

February 14-17, 2025

Register Now!

Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)

View More

Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)

View More

Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)

View More

Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)

View More

Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)

View More

Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)

View More

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)

View More

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)

View More

Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)

View More

Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)

View More

Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)

View More

More News

© 2024 MJH Life Sciences

All rights reserved.